Navigation Links
Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
Date:8/13/2008

each year, half are in the age range (18 to 54) most appropriate for PST risk assessment.

About PST(R) Genetic Test

PST(R) Genetic Test is a reliable way of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss. PST(R) Genetic Test is the first and only genetic test that analyzes interleukin 1 (IL1) genes for variations that identify an individual's predisposition for over-expression of inflammation and risk for more severe periodontal disease. The PST(R) Genetic Test was developed following numerous clinical studies, and more than 40 peer-reviewed articles have been published on the test.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment.

Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com .

About OralDNA Labs

OralDNA Labs, Inc. is a specialty diagnostic company c
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
2. Interleukin Genetics to Present at 2008 BIO International Convention
3. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
4. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
5. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
7. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
9. Interleukin Genetics Retains Top Life Science Communications Firms
10. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
11. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Synthetic protein mimics structure, function of metalloprotein in nature 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Chindex International Inc to Report Second Quarter Fiscal 2010 Financial Results 5675 1Chindex International Inc to Report Second Quarter Fiscal 2010 Financial Results 5675 2Dr Siegal 26apos 3Bs Cookie Diet Book by Obesity Expert Sanford Siegal D O M D Cracks Amazon Top 500 60049 1Dr Siegal 26apos 3Bs Cookie Diet Book by Obesity Expert Sanford Siegal D O M D Cracks Amazon Top 500 60049 2Dr Siegal 26apos 3Bs Cookie Diet Book by Obesity Expert Sanford Siegal D O M D Cracks Amazon Top 500 60049 3Dr Siegal 26apos 3Bs Cookie Diet Book by Obesity Expert Sanford Siegal D O M D Cracks Amazon Top 500 60049 4FDA Determines VYVANSE 28R 29 was Properly Granted Five Year Market Exclusivity 5672 1FDA Determines VYVANSE 28R 29 was Properly Granted Five Year Market Exclusivity 5672 2FDA Determines VYVANSE 28R 29 was Properly Granted Five Year Market Exclusivity 5672 3